BIAFINE® emulsion is not and does not contain a sunblock. Avoid direct exposure to the sun of body parts being treated with BIAFINE®.
In case of severe burns, consult a doctor.
In cases where BIAFINE® has been prescribed to treat radiation burns, it should not be applied within the 3 hours preceding a radiotherapy session. Avoid using this emulsion for prolonged periods and over large areas without the advice of your doctor.
Keep out of the reach of children.
BIAFINE® is non-toxic, it is for topical use only and should not be ingested or taken internally.
Following the application of BIAFINE® a temporary tingling sensation may occur (lasting 10 to 15 minutes), which is transient and subsides shortly afterwards. This is considered normal and is not an effect that necessitates the interruption of treatment.
BIAFINE® must not be used as a beauty care product on healthy skin.
If the wound continues to spread after a while or the wound still does not heal after one week, it is recommended to consult a doctor. This is also the case when the edges of the wound redden significantly, when the appearance of the wound suddenly detriorates, or when the wound becomes increasingly painful or is accompanied by fever (risk of infection).
For more details, always read the Package Information Leaflet, which is found in each packet, before use.
Special Precautions for Use
For the treatment of any dermal wound, always consult a physician. Use BIAFINE® only as directed. Extended, deeply fouled and deep wounds, as well as animal bites should be immediately seen to by a doctor (due to risk of a tetanus infection).
BIAFINE® should not be used if you are allergic to any of its constituents. It should not be applied to infected or heavily bleeding lesions. Do not use on mucous membranes and near eyes.
If you experience undesirable effects not mentioned here or in the Package Information leaflet, accompanying each pack, please speak with your doctor or pharmacist or report via the French National Agency for Medicine and Health Products Safety (Agence Nationale de Sécurité du Médicament et des produits de santé) and the French network of Regional Pharmacovigilance Centers Website: signalement-sante.gouv.fr and the Malta Medicines Authority, medicinesauthority.gov.mt/reportingadversereactions
